Saudi Chemical Company Holding Announces Signing Exclusive Agreement by Its Subsidiary AJA Pharma with Bioventure for the Drug “Ruxolitinib”

Saudi Chemical Company Holding Announces Signing Exclusive Agreement by Its Subsidiary AJA Pharma with Bioventure for the Drug “Ruxolitinib”

|Element List||Explanation|

|Announcement Detail|| Saudi Chemical Company Holding (SCCH), through its pharmaceutical sector represented by AJA Pharmaceutical Industries Ltd. (AJA Pharma), announces signing an exclusive agreement with Bioventure FZ-LLC, a subsidiary of GlobalOne Healthcare Holding (GHH) on Tuesday, 09071444H corresponding to, 31012023 , in the Saudi Export stand during Arab Health Exhibition 2023, where AJA Pharma will get exclusive licensing rights for the drug “Ruxolitinib”. which is a type of cancer drug, used to treat some types of neoplasms.

|

Under this agreement, AJA Pharma will have exclusive commercialization rights of Ruxolitinib in the Kingdom of Saudi Arabia, the rest of the GCC, and Levant countries. AJA Pharma will also have rights to the transfer of technology in the future for the manufacturing of the drug in Saudi Arabia.

By this agreement, AJA Pharma aims at strengthening its position in Saudi and Global markets in the field of Oncology, Diabetes and Specialty products, to serve and meet community needs in line with Saudi Vision’s objectives 2030 to localize value-added specialty drugs